Analyst consensus rating
Coherus Oncology Analyst Rating: Strong Buy
Direct answer
Coherus Oncology's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.75.
Forecast evidence checked November 9, 2026.
Get free Coherus Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.77
- Average price target
- $7.75
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +419.5%
- Target upside
- +906.5%
- High target gap
- +1,198.7%
- Target range width
- 779.2%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- November 9, 2026
- Valid through
- November 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Coherus Oncology?
Coherus Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $7.75.
How far are Coherus Oncology's low and high targets from the recorded price?
The low target implies +419.5%, while the high target implies +1,198.7%.
How many analysts are included in Coherus Oncology's consensus?
The verified consensus includes 4 analysts.
How is Coherus Oncology's target upside or downside calculated?
The average target of $7.75 is divided by the recorded price of $0.77, then one is subtracted to produce +906.5%. This does not guarantee a future return.
When was Coherus Oncology's analyst forecast verified?
The data was verified on 2026-11-09. The dataset is valid through 2026-11-16.